What drug is suitable for cabozantinib resistance?

The selection of appropriate medication after cabozantinib resistance is a complex issue that needs to be comprehensively considered based on the patient's specific situation and genetic mutation information. Here are some possible alternative medication options:

1.Sunitinib (Sunitinib): This is a drug that targets tyrosine kinase and is mainly used to treat kidney cancer. Although there is no direct evidence in the treatment of cabozantinib resistance, physicians may consider tinitinide as an alternative treatment depending on the specific circumstances of some patients.

2.Lenvatinib (Lenvatinib): It is a targeted drug that inhibits angiogenesis and is suitable for the treatment of liver cancer and thyroid cancer. For patients with cabozantinib-resistant liver cancer, raltetiamide may be an effective alternative. Meanwhile, in patients with thyroid cancer, doctors may consider combining raltimid with everolimus.

3.Everolimus (Everolimus): This is an oral targeted therapy drug that can be used to treat liver cancer and kidney cancer. It helps control tumor growth by inhibiting signaling pathways such as targeted tyrosine kinases and mTOR. Everolimus may serve as a potential alternative treatment in the setting of cabozantinib resistance.

4.Rasatinib (Larotrectinib): For tumors with NTRK gene fusion positivity, rasatinib is an effective targeted inhibitor. It works across a variety of cancer types, including kidney, liver and thyroid cancers, among others. Therefore, in the setting of cabozantinib resistance, rasartinib may be an appropriate treatment option if the patient's tumor has an NTRK gene fusion.

In addition, there are some new targeted drugs undergoing clinical trials, such as apatinib (Apatinib) and posimetinib (Pexdartinib). The efficacy and safety of these drugs are still being evaluated, but they may become effective alternative treatment options in the future after cabozantinib resistance.